Nuvalent (NUVL) Operating Income (2020 - 2026)
Nuvalent (NUVL) posted Operating Income of -$119.4 million for Q1 2026, down 16.8% on a QoQ basis from -$102.2 million in Q4 2025, and down 25.94% year-over-year from -$161.2 million in Q1 2025.
Nuvalent (NUVL) Operating Income (2020 - 2026) Analysis & Trends
Nuvalent's Operating Income history runs 7 years deep, the most recent figure standing at -$119.4 million for Q1 2026.
- Quarterly Operating Income fell 25.94% year-over-year to -$119.4 million in Q1 2026, while the trailing twelve-month figure through Mar 2026 was -$438.9 million (down 36.05% YoY) and the FY2025 annual result came in at -$414.3 million, down 47.77% from the prior year.
- Operating Income was -$119.4 million for Q1 2026 at Nuvalent, down from -$102.2 million in the prior quarter.
- Across five years, Operating Income topped out at -$17.7 million in Q1 2022 and bottomed at -$119.4 million in Q1 2026.
- A 5-year average of -$61.7 million and a median of -$52.6 million in 2024 frame the typical range for Operating Income.
- Annual changes were most pronounced in 2022 — Operating Income plunged 187.05% — and 2025, when it slipped 18.46%.
- Nuvalent's Operating Income stood at -$29.3 million in 2022, then slumped by 58.49% to -$46.4 million in 2023, then slumped by 85.84% to -$86.3 million in 2024, then decreased by 18.46% to -$102.2 million in 2025, then dropped by 16.8% to -$119.4 million in 2026.
- Business Quant data shows NUVL's Operating Income at -$119.4 million in Q1 2026, -$102.2 million in Q4 2025, and -$112.7 million in Q3 2025.
Powered by 
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | Op. Inc (Qtr) |
|---|---|---|---|---|---|
| 1 | Oculis Holding AG | 67,072.09 Bn | 67,072.09 Bn | - | -27.75 Mn |
| 2 | Nanobiotix | 1,894.61 Bn | 1,894.55 Bn | - | - |
| 3 | Akari Therapeutics | 1,014.18 Bn | 1,014.18 Bn | - | -15.76 Mn |
| 4 | BeOne Medicines | 471.64 Bn | 466.85 Bn | 1.35 Bn | 249.90 Mn |
| 5 | Vertex Pharmaceuticals | 121.72 Bn | 114.47 Bn | 2.59 Bn | 1.14 Bn |
| 6 | Regeneron Pharmaceuticals | 68.28 Bn | 59.52 Bn | 3.31 Bn | 642.90 Mn |
| 7 | Belite Bio | 61.40 Bn | 61.40 Bn | - | -32.68 Mn |
| 8 | Argenx Se | 56.94 Bn | 56.94 Bn | 1.18 Bn | 394.00 Mn |
| 9 | Revolution Medicines | 37.37 Bn | 37.37 Bn | - | -445.22 Mn |
| 10 | Nuvalent | 9.75 Bn | 9.75 Bn | - | -119.41 Mn |
Historic Data
Download Data| Date | Value |
|---|---|
| Mar 31, 2026 | -119.41 Mn |
| Dec 31, 2025 | -102.23 Mn |
| Sep 30, 2025 | -112.70 Mn |
| Jun 30, 2025 | -104.57 Mn |
| Mar 31, 2025 | -94.81 Mn |
| Dec 31, 2024 | -86.30 Mn |
| Sep 30, 2024 | -76.33 Mn |
| Jun 30, 2024 | -65.15 Mn |
| Mar 31, 2024 | -52.59 Mn |
| Dec 31, 2023 | -46.44 Mn |
| Sep 30, 2023 | -38.78 Mn |
| Jun 30, 2023 | -34.06 Mn |
| Mar 31, 2023 | -30.21 Mn |
| Dec 31, 2022 | -29.30 Mn |
| Sep 30, 2022 | -20.39 Mn |
| Jun 30, 2022 | -18.73 Mn |
| Mar 31, 2022 | -17.69 Mn |
| Dec 31, 2021 | -17.38 Mn |
| Sep 30, 2021 | -12.43 Mn |
| Jun 30, 2021 | -9.85 Mn |